The Technical Analyst
Select Language :
Recursion [RXRX]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology

Recursion Price, Forecast, Insider, Ratings, Fundamentals & Signals

Current Signal: BUY (auto-tracking)

Recursion is listed at the  Exchange

-1.45% $10.17

America/New_York / 27 mar 2024 @ 16:00


FUNDAMENTALS
MarketCap: 2 194.98 mill
EPS: -1.580
P/E: -6.44
Earnings Date: May 05, 2024
SharesOutstanding: 215.83 mill
Avg Daily Volume: 7.16 mill
RATING 2024-03-27
B-
Neutral
RATINGS
Rating CashFlow: Neutral
Return On Equity: Sell
Return On Asset: Sell
DE: Sell
P/E: Strong Sell
Price To Book: Strong Buy
QUARTER GROWTHS
3/224/221/232/233/234/23
Revenue
Gr.Profit
Ebit
Asset
Debt
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE -6.44 | sector: PE -3.05
PE RATIO: COMPANY / INDUSTRY
-1.10x
Company: PE -6.44 | industry: PE 5.88
DISCOUNTED CASH FLOW VALUE
N/A
N/A
Expected Trading Range (DAY)

$ 8.98 - 11.36

( +/- 11.66%)
ATR Model: 14 days

Insider Trading

Date Person Action Amount type
2024-03-21 Marriott Tina Buy 8 000 Class A Common Stock
2024-03-21 Marriott Tina Sell 7 390 Class A Common Stock
2024-03-21 Marriott Tina Sell 610 Class A Common Stock
2024-03-21 Marriott Tina Sell 8 000 Stock Option (Right to Buy)
2024-03-19 Borgeson Blake Sell 20 054 Class A Common Stock
INSIDER POWER
47.35
Last 100 transactions
Buy: 2 830 923 | Sell: 1 011 721

Forecast: 16:00 - $10.18

Live Trading Signals (every 1 min)

Forecast 1: 16:00 - $10.18
Forecast 2: 16:00 - $10.18
Forecast 3: 16:00 - $10.18
SCORE
-10.00
Sell
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $10.17 (-1.45% )
Volume 3.92 mill
Avg. Vol. 7.16 mill
% of Avg. Vol 54.70 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Recursion Pharmaceuticals, Inc.

Last 12 Months

Last 12 months chart data with high, low, open and close for Recursion Pharmaceuticals, Inc.

RSI

Intraday RSI14 chart for Recursion Pharmaceuticals, Inc.

Last 10 Buy & Sell Signals For RXRX

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Feb 8 - 15:35buy$10.01N/AActive
Profile picture for
            Recursion Pharmaceuticals, Inc.

RXRX

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Last 10 Buy Signals

Date Signal @
BONDUSDMar 28 - 05:466.14
RDNTUSDMar 28 - 05:440.335
SETH2USDMar 28 - 05:443 496.64
SAVAXUSDMar 28 - 05:4461.90
GNSUSDMar 28 - 05:445.11
INDEXUSDMar 28 - 05:445.94
FNSAUSDMar 28 - 05:4435.73
ANKRETHUSDMar 28 - 05:444 103.36
XU100.ISMar 28 - 05:30PTS8 970.91
XBANK.ISMar 28 - 05:2910 827

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.